Skip to main content

Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.

Publication ,  Conference
Wheeler, SB; Spees, L; Jackson, BE; Baggett, C; Wilson, LE; Greiner, MA; George, DJ; Scales, CD; Pritchard, J; Dinan, MA
Published in: Journal of Clinical Oncology
February 20, 2021

279 Background: Availability of targeted oral anti-cancer agents (OAA) has transformed care delivery for metastatic renal cell carcinoma (RCC) patients. Our objective was to identify patterns and predictors of OAA use within the 12 months after metastatic RCC was detected to understand the extent of real-world adoption of these treatment advances. Methods: We used a novel, North Carolina, registry-linked multi-payer claims data resource to examine patterns of use of sorafenib, sunitinib, pazopanib, everolimus, axitinib, cabozantinib, and levantinib in a cohort of metastatic RCC patients diagnosed over 10 years (2006-2015, with claims through 2016). Patients were required to have 12 months of pre- and post-metastatic-index-date continuous enrollment. Log-Poisson models estimated unadjusted and adjusted risk ratios (RRs) and 95% confidence limits (CLs) for associations between patient characteristics and OAA use. In sensitivity analyses, we used a competing risk framework to estimate adjusted risk differences (RD) in OAA use. Results: Our population-based study of 713 patients demonstrated relatively low (37%) OAA use at any time during the 12 months post-metastatic-index date among publicly and privately insured patients, with shifting patterns of use consistent with regulatory approvals over time. Lower OAA use was observed among patients who were older, frailer, and with greater comorbidity burden. Other patient-level characteristics, such as sex, race, rurality and type of insurance were not significant predictors of OAA use. Conclusions: These data underscore the importance of distinguishing clinically appropriate from potentially poor-quality care and warrant additional studies to understand in more depth the system, provider and patient level drivers of these patterns.

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 20, 2021

Volume

39

Issue

6_suppl

Start / End Page

279 / 279

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wheeler, S. B., Spees, L., Jackson, B. E., Baggett, C., Wilson, L. E., Greiner, M. A., … Dinan, M. A. (2021). Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. In Journal of Clinical Oncology (Vol. 39, pp. 279–279). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2021.39.6_suppl.279
Wheeler, Stephanie B., Lisa Spees, Bradford E. Jackson, Christopher Baggett, Lauren E. Wilson, Melissa A. Greiner, Daniel J. George, Charles D. Scales, Jessica Pritchard, and Michaela Ann Dinan. “Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.” In Journal of Clinical Oncology, 39:279–279. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.279.
Wheeler SB, Spees L, Jackson BE, Baggett C, Wilson LE, Greiner MA, et al. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 279–279.
Wheeler, Stephanie B., et al. “Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.Journal of Clinical Oncology, vol. 39, no. 6_suppl, American Society of Clinical Oncology (ASCO), 2021, pp. 279–279. Crossref, doi:10.1200/jco.2021.39.6_suppl.279.
Wheeler SB, Spees L, Jackson BE, Baggett C, Wilson LE, Greiner MA, George DJ, Scales CD, Pritchard J, Dinan MA. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 279–279.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 20, 2021

Volume

39

Issue

6_suppl

Start / End Page

279 / 279

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences